Adding Smiles To Life

Date: November 14, 2024

To
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400051, Maharashtra.

SYMBOL: QMSMEDI

Sub: Outcome of Board meeting

Re: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Ma'am,

With reference to the captioned subject, we wish to inform that the Board of Directors of the Company in its meeting held today, i.e. on November 14, 2024, have inter-alia considered and approved the following:

Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2024:

Copy of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2024 of the financial year 2024-25 is enclosed herewith.

The aforesaid results were reviewed by the Audit Committee and subsequently, approved and taken on record by the Board of Directors of the Company. We would further like to inform that the Statutory Auditors of the Company have subjected the aforesaid results to "Limited Review" and the same is enclosed herewith.

QMS Medical Allied Services Ltd.
1A-1B / 2A-2B, Navkala Bharati Building, Plot No. 16, Prabhat Colony, Road No. 3, Santacruz (East), Mumbai - 400 055.
+91-022 - 6288 1111 www.qmsmas.com
CIN: L33309MH2017PLC299748; Email ID: mm@qmsmas.com

Adding Smiles To Life

The meeting commenced at 3.30 PM and concluded at 4.30 P.M.

This is for your information and records.

Thanking you,

Yours sincerely,

FOR QMS MEDICAL ALLIED SERVICES LIMITED

TORAL JAILESH BHADRA

Digitally signed by TORAL JAILESH BHADRA
Date: 2024.11.14 16:35:53 +05'30'

TORAL BHADRA
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO.: A56927
DATE: NOVEMBER 14, 2024
PLACE: MUMBAI

Independent Auditor's report on quarterly unaudited standalone financial results of QMS Medical Allied Services Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
QMS Medical Allied Services Limited

Introduction

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of QMS Medical Allied Services Limited ("the Company") for the quarter ended on September 30, 2024, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Management's Responsibility

2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard ("AS") 25 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

Auditor's Responsibility

3. Our responsibility is to issue a report on the statement based on our review.

Scope of Review

4. We conducted our review of the statement in accordance with the Standard on Review Engagements ("SRE") 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical and other review procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable

H. H. DEDHIA & ASSOCIATES MUMBAI

AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter

6. The standalone financial results pertaining to corresponding quarter ended as well as half year ended September 30, 2023 in the Statement were reviewed by the previous auditors and the financial statements for the year ended March 31, 2024 were audited by the predecessor auditors, who had expressed an unmodified opinion/ conclusion on that financial information.

7. The figures for the quarter ended September 30, 2024 are the balancing figures between the unaudited half year ended September 30, 2024 and unaudited figures for the quarter ended June 30, 2024 which were subject to limited review by the previous auditor.

For **H H Dedhia & Associates**
Chartered Accountants
(FRN – 148213W)

H.H. DEDHIA & ASSOCIATES MUMBAI

Harsh H. Dedhia
Proprietor
M No. – 141494
UDIN – **24141494BKEOHX1030**

Place: Mumbai
Date: November 14, 2024

QMS MEDICAL ALLIED SERVICES LIMITED
CIN:L33309MH2017PLC299748

Registered Office: A1 A2/B1 B2, Navkala Bharti Bldg Plot No16 Prabhat Colony opp near Santacruz Bus depot Santacruz East Mumbai 400055, Maharashtra, India
Email:mm@qmsmas.com **Web: https://qmsmas.com/**

Statement of Unaudited Standalone Financial Results for the quarter and half year ended 30th September 2024. (Rs. In Lacs)

Sn	Particulars	Quarter Ended			Six Months Ended		Year ended 31.03.2024
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Revenue From Operations**						
(a)	Revenue From Operations (Net of taxes)	3,274.04	3,036.74	2,864.39	6,310.78	5,460.29	12,212.80
(b)	Other Income	9.35	10.86	11.33	20.21	19.64	45.56
	Total Income (net)	**3,283.39**	**3,047.60**	**2,875.72**	**6,330.99**	**5,479.93**	**12,258.36**
2	**Expenses**						
(a)	Cost of Material Consumed	-	-	-	-	-	-
(b)	Purchase of Stock-in-Trade	1,843.76	1,912.01	1,840.80	3,755.77	3,655.29	8,757.74
(c)	Changes in Inventories of Finished Goods, Work in Progress and Stock in Trade	76.99	(190.16)	(12.58)	(113.18)	(193.29)	(765.31)
(d)	Employee Benefits Expenses	175.15	161.92	120.70	337.07	222.93	550.18
(e)	Finance Cost	106.86	84.15	73.72	191.01	132.83	312.56
(f)	Depreciation and Amortisation Expenses	82.77	76.74	85.52	159.51	167.25	344.00
(g)	Other Expenses	645.94	668.80	425.84	1,314.74	820.00	1,835.60
	Total Expenses	**2,931.46**	**2,713.46**	**2,534.01**	**5,644.92**	**4,805.01**	**11,034.78**
3	**Profit before exceptional and extraordinary items and tax**	**351.93**	**334.14**	**341.70**	**686.07**	**674.92**	**1,223.59**
4	Exceptional items						-
5	**Profit before extraordinary items and tax**	**351.93**	**334.14**	**341.70**	**686.07**	**674.92**	**1,223.59**
6	Extraordinary items	-	-	-	-	-	-
7	**Profit before tax**	**351.93**	**334.14**	**341.70**	**686.07**	**674.92**	**1,223.59**
8	Tax expense						
(a)	Current Tax	92.00	92.00	89.00	184.00	175.00	331.50
(b)	Deferred Tax	-1.25	2.57	(3.31)	1.32	(2.14)	(7.65)
(c)	(Excess)/Short Provision for earlier years	-	0.05	-	0.05	-	(0.51)
	Total Tax Expense	**90.75**	**94.62**	**85.69**	**185.37**	**172.86**	**323.34**
9	**Profit for the period from continuing operations**	**261.17**	**239.52**	**256.01**	**500.70**	**502.06**	**900.24**
10	Profit/(loss) from discontinuing operations						-
11	Profit/(Loss) for the period	**261.17**	**239.52**	**256.01**	**500.70**	**502.06**	**900.24**
12	**Details of Equity Share Capital**						
	Paid up equity share capital (Face value of Rs.10/- each)	**1,785.00**	**1,785.00**	**1,785.00**	**1,785.00**	**1,785.00**	**1,785.00**
	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						**6,066.38**
13	**Earnings Per Equity Share (before extraorinary items) (of Rs. 10/-each) (not annualised) (before and after extraordinary items)**						
(a)	Basic	**1.46**	**1.34**	**1.43**	**2.81**	**2.81**	**5.04**
(b)	Diluted	**1.46**	**1.34**	**1.43**	**2.81**	**2.81**	**5.04**
	See accompanying note to Financial Results						

FOR QMS MEDICAL ALLIED SERVICES LIMITED

QMS MEDICAL ALLIED SERVICES LIMITED MUMBAI

Mr. MAHESH PAHALRAJ MAKHIJA
Managing Director
DIN: 02700606

Date: 14th November, 2024
Place: Mumbai

QMS MEDICAL ALLIED SERVICES LIMITED

Regd. Office: Office No A1 A2/B1 B2, Navkala Bharti Bldg, Plot No16, Prabhat Colony, Opp near Santacruz Bus depot, Santacruz East, Mumbai - 400055.

CIN No: L33309MH2017PLC299748

Statement of Standalone Assets and Liabilities

(Rs. In lakhs)

PARTICULARS			As at September 30,2024 (Unaudited)	As at March 31,2024 (Audited)
(I)	**EQUITY AND LIABILITIES**			
1)	**Shareholders' Funds**			
	(a)	Share Capital	1,785.00	1,785.00
	(b)	Reserves and Surplus	6,567.08	6,066.38
	(c)	Money received against share warrants	-	-
2)	**Non - Current Liabilities**			
	(a)	Long-term borrowings	2,799.73	237.41
	(b)	Deferred tax liabilities (Net)	33.05	31.73
	(c)	Other Long term liabilities	-	-
	(d)	Long-term provisions	17.60	14.81
3)	**Current Liabilities**			
	(a)	Short Term borrowings	4,141.00	3,217.28
	(b)	Trade payables		
		Trade Payables-Micro and Small Enterprises	34.53	749.53
		Trade Payables- Other than Micro and Small Enterprises	1,294.03	1,229.36
	(c)	Other Current liabilities	155.36	92.64
	(d)	Short Term Provisions	214.60	107.92
			17,041.98	**13,532.05**
(II)	**ASSETS**			
1)	**Non Current Assets**			
	(a)	**Plant,Property and Equipment & Intangible Assets**		
		(i) Plant,Property and Equipment	2,271.02	2,328.29
		(ii) Intangible assets	34.05	29.28
		(iii) Capital work-in-progress	-	-
		(iv) Intangible assets under development	247.25	205.71
	(b)	Non Current Investments	4,528.01	-
	(c)	Deferred tax assets (net)	-	-
	(d)	Long Term Loans and Advances	295.00	325.00
	(e)	Other Non Current Assets	43.53	66.44
2)	**Current Assets**			
	(a)	Current investments	16.19	210.56
	(b)	Inventories	3,871.48	3,758.31
	(c)	Trade receivables	3,234.71	4,139.21
	(d)	Cash and cash equivalents	23.44	30.54
	(e)	Short-term loans and advances	399.34	393.39
	(f)	Other Current Assets	2,077.95	2,045.32
			17,041.98	**13,532.05**

FOR QMS MEDICAL ALLIED SERVICES LIMITED

QMS MEDICAL ALLIED SERVICES LIMITED MUMBAI

Mr. MAHESH PAHALRAJ MAKHIJA
Managing Director
DIN: 02700606

Date: 14th November, 2024
Place: Mumbai

QMS MEDICAL ALLIED SERVICES LIMITED

Regd. Office: Office No A1 A2/B1 B2, Navkala Bharti Bldg, Plot No16, Prabhat Colony, Opp near Santacruz Bus depot, Santacruz East, Mumbai - 400055.

CIN No: L33309MH2017PLC299748

Statement of Standalone Cash Flow for the half year ended Septemeber 30, 2024

(Rs. In lakhs)

Sn	Particulars	For the Year ended As at September 30,2024 (Unaudited)	As at September 30,2023 (Unaudited)
(A)	**OPERATING ACTIVITIES:**		
	Net Profit after tax	500.70	502.06
	(+) Current Tax	184.05	175.00
	(+/-) Deferred tax	1.32	(2.14)
	Net Profit before tax	**686.07**	**674.92**
	Adjustments to reconcile profit before tax to net cash flows :		
	Depreciation and amortisation expense	159.51	167.25
	Finance costs	33.05	8.56
	Interest on Loan and Fixed Deposit	(15.33)	-
	Profit on Sale of Fixed Assets	(1.64)	-
	Operating profit before working capital changes	**175.60**	**175.81**
	Working capital adjustments		
	Increase/(Decrease) in trade payables	(650.34)	(1,148.77)
	Increase/(Decrease) in Other current Liabilities	62.72	(33.46)
	Increase/(Decrease) in Provisions	109.47	3.25
	Increase/(Decrease) in Borrowings	786.09	802.09
	(Increase)/Decrease in Inventories	(113.18)	(219.66)
	(Increase)/Decrease in Trade receivables	904.50	810.43
	(Increase)/Decrease in Short Term loans and advances	(5.95)	66.44
	(Increase)/Decrease in Other current Assets	(32.62)	(488.66)
	Cash generated from operations	**1,060.70**	**(208.35)**
	Income tax paid	(184.05)	(175.00)
	Net cash flow from operating activities	**1,738.31**	**467.38**
(B)	**INVESTING ACTIVITIES**		
	Purchase of property, plant and equipment and intangibles (including work in progress and capital advances)	(154.37)	(127.18)
	Loans/Deposits advanced during the year		39.46
	Investment in Fixed Deposits	(5.64)	-
	Investment in Shares of Subsidiary	(4,528.01)	-
	Deposits received back	22.91	-
	Loans advanced received back	30.00	-
	Redemption of Fixed Deposits	205.00	-
	Interest Income on Loan and Fixed Depsoit	15.33	-
	Sale of Fixed Assets	7.45	-
	NET CASH FLOWS FROM/ (USED) IN INVESTING ACTIVITIES	**(4,407.32)**	**(87.72)**
(C)	**FINANCING ACTIVITIES**		
	Loan repayment	(175.04)	(40.13)
	Finance cost paid	(33.05)	(8.56)
	Dividend Paid	-	(89.25)
	Acceptance of Loan	2,875.01	-
	NET CASH FLOWS FROM/ (USED IN) FINANCING ACTIVITIES	**2,666.91**	**(137.94)**
	NET INCREASE / (DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C)	(2.10)	**241.72**
	Cash & Cash Equivalents at the beginning of the year	25.54	236.63
	Cash & Cash Equivalents at the end of the Period	23.44	478.35

FOR QMS MEDICAL ALLIED SERVICES LIMITED

QMS MEDICAL ALLIED SERVICES LIMITED MUMBAI

Mr. MAHESH PAHALRAJ MAKHIJA
Managing Director
DIN: 02700606

Date: 14th November, 2024
Place: Mumbai

Adding Smiles To Life

Notes to Standalone Financial Statements

1. The above unaudited financial results of the company were reviewed by the Audit Committee & approved by the Board of Directors at its meeting held on 14th November 2024. The auditors have expressed an unmodified opinion on the said financial results.
2. The results of the Company are available for investors at www.qmsmas.com and www.nseindia.com.
3. The standalone financial results for the quarter ended on 30th September, 2024 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results.
4. The Company is operating as a single segment company, engaged in "Healthcare Equipments/Supplies and Services" and hence there is no separate reportable business segment.
5. As per MCA notification dated 16 February, 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of capital & Disclosure Requirements) Regulations, 2009 are exempted from compulsory requirement of adoption of IND-AS, as the company is covered under the exempted category, it has not adopted IND-AS for preparation of financial results.
6. On 05th July 2024, The Company acquired 51% equity shareholding in Saarathi Healthcare Private Limited (referred to as "Subsidiary"). The Company has acquired 51% shareholding of the company for purchase consideration of Rs. 4,528.01 lakhs.
7. There are no Investor complaints pending as on 30th September 2024.
8. The figures for the quarter ended 30th September 2024 are balancing figures between the figures of the half year ended 30th September 2024 which were subject to limited review and figures for the quarter ended 30th June 2024.
9. The figures for the quarter ended 30th September 2023 are balancing figures between the figures of the half year ended 30th September 2023 which were subject to limited review and figures for the quarter ended 30th June 2023 which were subjected to limited review by statutory auditor.
10. Previous year figures have been regrouped/reclassified where required to make them comparable with figures of current period.

For & on behalf of the Board of Directors of
QMS Medical Allied Services Limited

QMS MEDICAL ALLIED SERVICES LIMITED MUMBAI

Mahesh Makhija
Managing Director
[DIN: 02700606]

1A-1B / 2A-2B, Navkala Bharati Building, Plot No. 16, Prabhat Colony, Road No. 3, Santacruz (East), Mumbai - 400 055.
+91-022 - 6288 1111 www.qmsmas.com mm@qmsmas.com

Limited Review Report on quarterly unaudited consolidated financial results of QMS Medical Allied Services Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
QMS Medical Allied Services Limited

Introduction

1. We have reviewed the accompanying statement of unaudited consolidated financial results ("the Statement") of QMS Medical Allied Services Limited (hereinafter referred to as "the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended on September 30, 2024, attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Management's Responsibility

2. This statement, which is the responsibility of the Parent's Management and approved by the Board of Directors of the Parent, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard ("AS") 25 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

Auditor's Responsibility

3. Our responsibility is to express a conclusion on the statement based on our review.

Scope of Review

4. We conducted our review of the statement in accordance with the Standard on Review Engagements ("SRE") 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical and other review procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

H.H. DEDHIA & ASSOC. MUMBAI

We also performed procedures in accordance with the circular issued by Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
Statement includes the results of the following entities

Sr. No.	Name of Entity	Relationship
1	Saarthi Healthcare Private Limited	Subsidiary

Conclusion

5. Based on our review conducted and procedures performed as stated in paragraph 4 above and based on the management certified financial statements referred to in paragraph 7, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter

6. The Financial Results pertaining to corresponding quarter ended as well as half year ended September 30, 2023 in the Statement were reviewed by the previous auditors and the financial statements for the year ended March 31, 2024 were audited by the predecessor auditors, who had expressed an unmodified opinion/ conclusion on that financial information.

7. We did not review the interim financial information/ financial results of subsidiary included in the statement, whose interim financial information/ financial results reflects total income of Rs. 469.27 lakhs, total net profit after tax of Rs. 162.16 lakhs for the half year ended September 30, 2024, as considered in the statement. These interim financial information/ financial results have been certified by management which have been furnished to us by the Parent's management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary is based solely on the reports of the other auditor and procedures performed by us stated in paragraph 4 above. Our conclusion is not modified in respect of this matter.

8. The figures for the quarter ended September 30, 2024 are the balancing figures between the unaudited half year ended September 30, 2024 and unaudited figures for the quarter ended June 30, 2024 which were subject to limited review by the previous auditor.

H.H. DEDHIA & ASSOCIATES
MUMBAI

For **H H Dedhia & Associates**
Chartered Accountants
(FRN – 148213W)

Harsh H. Dedhia
Proprietor
M No. – 141494
UDIN – **24141494BKEOHY9143**

Place: Mumbai
Date: November 14, 2024

QMS MEDICAL ALLIED SERVICES LIMITED

CIN:L33309MH2017PLC299748

Registered Office: A1 A2/B1 B2, Navkala Bharti Bldg Plot No16 Prabhat Colony opp near Santacruz Bus depot Santacruz East Mumbai 400055, Maharashtra, India

Email:mm@qmsmas.com **Web: https://qmsmas.com/**

Statement of Unaudited Consolidated Financial Results for the quarter and half year ended 30th September 2024. (Rs. In Lakhs)

Sn	Particulars	Quarter Ended			Six Months Ended		Year ended 31.03.2024
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Revenue From Operations**						
(a)	Revenue From Operations (Net of taxes)	3,719.88	3,036.74	2,864.39	6,756.63	5,460.29	12,212.80
(b)	Other Income	32.78	10.86	11.33	43.64	19.64	45.56
	Total Income (net)	**3,752.66**	**3,047.60**	**2,875.72**	**6,800.27**	**5,479.93**	**12,258.36**
2	**Expenses**						
(a)	Cost of Material Consumed	-	-	-	-	-	-
(b)	Purchase of Stock-in-Trade	1,844.36	1,912.01	1,840.80	3,756.37	3,655.29	8,757.74
(c)	Changes in Inventories of Finished Goods, Work in Progress and Stock in Trade	76.99	(190.16)	(12.58)	(113.18)	(193.29)	(765.31)
(d)	Employee Benefits Expenses	258.00	161.92	120.70	419.92	222.93	550.18
(e)	Finance Cost	106.93	84.15	73.72	191.08	132.83	312.56
(f)	Depreciation and Amortisation Expenses	83.62	76.74	85.52	160.37	167.25	344.00
(g)	Other Expenses	816.45	668.80	425.84	1,485.25	820.00	1,835.60
	Total Expenses	**3,186.35**	**2,713.46**	**2,534.01**	**5,899.81**	**4,805.01**	**11,034.78**
3	**Profit before exceptional and extraordinary items and tax**	**566.32**	**334.14**	**341.70**	**900.46**	**674.92**	**1,223.59**
4	Exceptional items						-
5	**Profit before extraordinary items and tax**	**566.32**	**334.14**	**341.70**	**900.46**	**674.92**	**1,223.59**
6	Extraordinary items	-	-	-	-	-	-
7	**Profit before tax**	**566.32**	**334.14**	**341.70**	**900.46**	**674.92**	**1,223.59**
8	Tax expense						
(a)	Current Tax	144.62	92.00	89.00	236.62	175.00	331.50
(b)	Deferred Tax	-1.63	2.57	(3.31)	0.94	(2.14)	(7.65)
(c)	(Excess)/Short Provision for earlier years	-	0.05	-	0.05	-	(0.51)
	Total Tax Expense	**142.98**	**94.62**	**85.69**	**237.60**	**172.86**	**323.34**
9	**Profit for the period from continuing operations**	**423.33**	**239.52**	**256.01**	**662.86**	**502.06**	**900.24**
10	Profit/(loss) from discontinuing operations						-
11	Profit/(Loss) for the period	**423.33**	**239.52**	**256.01**	**662.86**	**502.06**	**900.24**
	Profit for the period attributable to:						
	Owners of the compny	**343.87**	**239.52**	**256.01**	**583.40**	**502.06**	**900.24**
	Non-controlling Interest	**79.46**	-	-	**79.46**	-	-
12	**Details of Equity Share Capital**						
	Paid up equity share capital (Face value of Rs.10/- each)	**1,785.00**	**1,785.00**	**1,785.00**	**1,785.00**	**1,785.00**	**1,785.00**
	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						**6,066.38**
13	**Earnings Per Equity Share (before extraorinary items) (of Rs. 10/-each) (not annualised) (before and after extraordinary items)**						
(a)	Basic	**1.93**	**1.34**	**1.43**	**3.27**	**2.81**	**5.04**
(b)	Diluted	**1.93**	**1.34**	**1.43**	**3.27**	**2.81**	**5.04**
	See accompanying note to Financial Results						

FOR QMS MEDICAL ALLIED SERVICES LIMITED

QMS MEDICAL ALLIED SERVICES LIMITED MUMBAI

Mr. MAHESH PAHALRAJ MAKHIJA
Managing Director
DIN: 02700606

Date: 14th November, 2024
Place: Mumbai

QMS MEDICAL ALLIED SERVICES LIMITED

Regd. Office: Office No A1 A2/B1 B2, Navkala Bharti Bldg, Plot No16, Prabhat Colony, Opp near Santacruz Bus depot, Santacruz East, Mumbai - 400055.

CIN No: L33309MH2017PLC299748

Statement of Consolidated Assets and Liabilities

(Rs. In lakhs)

PARTICULARS			As at September 30,2024 (Unaudited)	As at March 31,2024 (Audited)
(I)	**EQUITY AND LIABILITIES**			
1)	**Shareholders' Funds**			
	(a)	Share Capital	1,785.00	1,785.00
	(b)	Reserves and Surplus	6,649.78	6,066.38
	(c)	Money received against share warrants	-	-
		Minority Interest	1,657.75	-
2)	**Non - Current Liabilities**			
	(a)	Long-term borrowings	967.17	237.41
	(b)	Deferred tax liabilities (Net)	33.67	31.73
	(c)	Other Long term liabilities	-	-
	(d)	Long-term provisions	17.60	14.81
3)	**Current Liabilities**			
	(a)	Short Term borrowings	4,141.00	3,217.28
	(b)	Trade payables	-	
		Trade Payables-Micro and Small Enterprises	34.53	749.53
		Trade Payables- Other than Micro and Small Enterprises	1,337.84	1,229.36
	(c)	Other Current liabilities	311.33	92.64
	(d)	Short Term Provisions	249.05	107.92
			17,184.71	**13,532.05**
(II)	**ASSETS**			
1)	**Non Current Assets**			
	(a)	**Plant,Property and Equipment & Intangible Assets**		
		(i) Plant,Property and Equipment	2,405.00	2,328.29
		(ii) Intangible assets	66.71	29.28
		(iii) Goodwill on acquisition	2,885.28	-
		(iv) Intangible assets under development	247.25	205.71
	(b)	Non Current Investments	-	-
	(c)	Deferred tax assets (net)	-	-
	(d)	Long Term Loans and Advances	1,225.00	325.00
	(e)	Other Non Current Assets	72.64	66.44
2)	**Current Assets**			
	(a)	Current investments	134.42	210.56
	(b)	Inventories	3,871.48	3,758.31
	(c)	Trade receivables	3,498.15	4,139.21
	(d)	Cash and cash equivalents	48.20	30.54
	(e)	Short-term loans and advances	399.34	393.39
	(f)	Other Current Assets	2,331.24	2,045.32
			17,184.71	**13,532.05**

FOR QMS MEDICAL ALLIED SERVICES LIMITED

QMS MEDICAL ALLIED SERVICES LIMITED MUMBAI

Mr. MAHESH PAHALRAJ MAKHIJA
Managing Director
DIN: 02700606

Date: 14th November, 2024
Place: Mumbai

QMS MEDICAL ALLIED SERVICES LIMITED

Regd. Office: Office No A1 A2/B1 B2, Navkala Bharti Bldg, Plot No16, Prabhat Colony, Opp near Santacruz Bus depot, Santacruz East, Mumbai - 400055.

CIN No: L33309MH2017PLC299748

Statement of Consolidated Cash Flow for the half year ended Septemeber 30, 2024

(Rs. In lakhs)

Sn	Particulars	For the Year ended	
		As at September 30,2024 (Unaudited)	As at September 30,2023 (Unaudited)
(A)	**OPERATING ACTIVITIES:**		
	Net Profit after tax	662.86	502.06
	(+) Current Tax	236.67	175.00
	(+/-) Deferred tax	0.94	(2.14)
	Net Profit before tax	**900.46**	**674.92**
	Adjustments to reconcile profit before tax to net cash flows :		
	Depreciation and amortisation expense	160.37	167.25
	Finance costs	33.05	8.56
	Interest on Loan and Fixed Deposit	(38.76)	-
	Profit on Sale of Fixed Assets	(1.64)	-
	Operating profit before working capital changes	**153.02**	**175.81**
	Working capital adjustments		
	Increase/(Decrease) in trade payables	(788.96)	(1,148.77)
	Increase/(Decrease) in Other current Liabilities	178.06	(33.46)
	Increase/(Decrease) in Provisions	114.27	3.25
	Increase/(Decrease) in Borrowings	786.09	802.09
	(Increase)/Decrease in Inventories	(113.18)	(219.66)
	(Increase)/Decrease in Trade receivables	810.01	810.43
	(Increase)/Decrease in Short Term loans and advances	(5.95)	66.44
	(Increase)/Decrease in Other current Assets	(102.41)	(488.66)
	Cash generated from operations	**877.93**	**(208.35)**
	Income tax paid	(236.67)	(175.00)
	Net cash flow from operating activities	**1,694.75**	**467.38**
(B)	**INVESTING ACTIVITIES**		
	Purchase of property, plant and equipment and intangibles (including work in progress and capital advances)	(165.46)	(127.18)
	Loans/Deposits advanced during the year		39.46
	Investment in Fixed Deposits	(5.64)	-
	Investment in Shares of Subsidiary	(4,528.01)	-
	Deposits received back	45.86	-
	Loans advanced received back	30.00	-
	Redemption of Fixed Deposits	286.77	-
	Interest Income on Loan and Fixed Depsoit	38.76	-
	Sale of Fixed Assets	7.45	-
	NET CASH FLOWS FROM/ (USED) IN INVESTING ACTIVITIES	**(4,290.27)**	**(87.72)**
(C)	**FINANCING ACTIVITIES**		
	Loan repayment	(175.04)	(40.13)
	Finance cost paid	(33.05)	(8.56)
	Dividend Paid		(89.25)
	Acceptance of Loan	2,803.44	-
	NET CASH FLOWS FROM/ (USED IN) FINANCING ACTIVITIES	**2,595.35**	**(137.94)**
	NET INCREASE / (DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C)	(0.17)	**241.72**
	Cash & Cash Equivalents at the beginning of the year	48.37	236.63
	Cash & Cash Equivalents at the end of the Period	48.20	478.35

FOR QMS MEDICAL ALLIED SERVICES LIMITED

QMS MEDICAL ALLIED SERVICES LIMITED MUMBAI

Mr. MAHESH PAHALRAJ MAKHIJA
Managing Director
DIN: 02700606

Date: 14th November, 2024
Place: Mumbai

Adding Smiles To Life

Notes:

1. The above unaudited consolidated financial results of the company were reviewed and recommended by the audit committee on 14th November, 2024 and subsequently approved by the Board of Directors at its meeting held on 14th November, 2024. The review report has been filed with stock exchange and is available on the Company's website.

2. On 01st July 2024, The Company acquired 51% equity shareholding in Saarathi Healthcare Private Limited (referred to as "Subsidiary"). The Company has acquired 51% shareholding of the company for purchase consideration of Rs. 4,528.01 lakhs (including expenses in relation to acquisition). These unaudited consolidated financial results include the results of the Subsidiary from the date of acquisition of control as per AS 21 "Consolidated Financial Statements". The acquisition of this entity has resulted in recognition of Goodwill amounting to Rs. 2,885.28 Lakhs as under:

Particulars	Rs. in Lakhs
Value of assets acquired (A)	1,771.60
(-) Value of liabilities acquired (B)	(128.88)
Value of net assets (C=A-B)	**1,642.72**
Value of consideration discharged	**4,528.01**
Goodwill on consolidation	**2,885.28**

3. The figures for the quarter ended 30th September, 2024 are balancing figures between the unaudited figures of the half year and the published year to date figures of the first quarter of the financial year which are subjected to limited review.

4. The consolidated financial results for the quarter ended 30th September, 2024 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued an unmodified report on unaudited financial results.

5. The above consolidated financial results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ('SEBI'), and the Accounting Standards (AS) prescribed under Section 133 of the Companies Act, 2013.

6. The Parent Company's and its subsidiary company's only identifiable reportable segment is "Healthcare Equipments/Supplies & Services" and hence disclosure of Segment wise information is not applicable under Accounting Standard – 17 "Segment Reporting".

7. Previous periods / year figures are regrouped and rearranged wherever necessary including on account of amendment in Division II to Schedule III of Companies Act 2013 to conform current period presentation.

8. The results of the Company are available for investors at www.qmsmas.com and www.nseindia.com.

For & On behalf of the Board of Directors
of QMS Medical Allied Services Limited.

QMS MEDICAL ALLIED SERVICES LIMITED MUMBAI

Mahesh Makhija
Managing Director
[DIN: 02700606]

Place: Mumbai
Date: 14th November, 2024